tofacitinib
- RxCUI
- 1357536
- RxNorm name
- tofacitinib
- Term type
- IN
- Status
- Active
- Updated
- 2026-07-23 06:55:39
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 122012
- Active start
- 122012
- Multiple ingredient
- NO
- Branded
- NO
Source Vocabulary Codes#
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TOFACITINIB | TOFACITINIB | Golden State Medical Supply, Inc. | 58b94979-55ad-839a-e063-6294a90ad812 | 2026-08-24 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | Edenbridge Pharmaceuticals LLC. | 576722e5-6639-452d-a5c3-33a064f19481 | 2026-08-17 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | Golden State Medical Supply, Inc. | 58f22c41-87d2-e745-e063-6394a90a962e | 2026-08-13 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | Novadoz Pharmaceuticals LLC | 253635c8-1ea7-41ba-b216-dea5e3305c47 | 2026-08-13 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| tofacitinib | TOFACITINIB | Zydus Pharmaceuticals USA Inc. | 179ffbb2-bedc-40e6-b77b-33d4f7832172 | 2026-08-07 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | Macleods Pharmaceuticals Limited | 9b654f0d-7705-4880-9e9d-ad3a51e56b56 | 2026-08-06 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | Apotex Corp. | 7d4f5cfa-35a8-1458-a609-f6b417946abb | 2026-08-04 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| TOFACITINIB | TOFACITINIB | Micro Labs Limited | ffa6819b-23a4-478b-8fb7-cc90e8142fc5 | 2026-07-31 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| tofacitinib | TOFACITINIB | Zydus Pharmaceuticals USA Inc. | 21a89264-8047-40ac-8b10-fa6461072509 | 2026-07-30 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| TOFACITINIB | TOFACITINIB | Sun Pharmaceutical Industries, Inc. | a764a133-b870-4514-bbee-24d43f8cb7fd | 2026-07-27 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | Apotex Corp. | dd62a2b8-300b-d92b-7b27-a30eaa68fdd3 | 2026-07-27 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | AvKARE | 5751321a-c904-44ae-e063-6394a90a2654 | 2026-07-23 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| TOFACITINIB | TOFACITINIB | Aurobindo Pharma Limited | e54b186f-e42a-4477-939c-8dd331045fbe | 2026-07-17 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| TOFACITINIB | TOFACITINIB | Aurobindo Pharma Limited | 50962b08-99dd-ae73-e063-6394a90ad1eb | 2026-07-17 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| TOFACITINIB | TOFACITINIB | IPG Pharmaceuticals, Inc | cd1b61bf-de03-4198-89f6-f3952b79d2c2 | 2026-07-15 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| XELJANZ | TOFACITINIB | U.S. Pharmaceuticals | 68e3d6b2-7838-4d2d-a417-09d919b43e13 | 2026-07-13 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| XELJANZ XR | TOFACITINIB | Pfizer Laboratories Div Pfizer Inc | cf74ba2f-afc5-4baa-8594-979c889a5831 | 2026-07-12 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| tofacitinib solution | TOFACITINIB | Hikma Pharmaceuticals USA Inc. | d9cf18a9-e825-49ac-b080-68957c0e79ae | 2026-07-01 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| TOFACITINIB | TOFACITINIB | Orient Pharma Co., Ltd. Yunlin Plant | 5617a652-a78e-74b1-e063-6394a90a31c7 | 2026-06-30 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
| Tofacitinib | TOFACITINIB | AvKARE | 5502f252-2b39-2cfd-e063-6394a90a8a48 | 2026-06-24 | Boxed warning, Warnings, Adverse reactions | TOFACITINIB |
DailyMed RxNorm Mappings#
No records found.
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | L04AF | Janus-associated kinase (JAK) inhibitors | ATC1-4 | tofacitinib | |
| FDASPL | N0000190858 | Janus Kinase Inhibitor | EPC | has_epc | tofacitinib |
| FDASPL | N0000190857 | Janus Kinase Inhibitors | MOA | has_moa | tofacitinib |
| MEDRT | D010880 | Piperidines | CHEM | has_ingredient | tofacitinib |
| MEDRT | D010880 | Piperidines | CHEM | has_ingredient | tofacitinib citrate |
| MEDRT | D011743 | Pyrimidines | CHEM | has_ingredient | tofacitinib |
| MEDRT | D001172 | Arthritis, Rheumatoid | DISEASE | may_treat | tofacitinib |
| MEDRT | D001172 | Arthritis, Rheumatoid | DISEASE | may_treat | tofacitinib citrate |
| MEDRT | N0000190857 | Janus Kinase Inhibitors | MOA | has_moa | tofacitinib |
| MEDRT | N0000190857 | Janus Kinase Inhibitors | MOA | has_moa | tofacitinib citrate |
| MEDRT | N0000008656 | Decreased Hematopoiesis | PE | has_pe | tofacitinib |
| MEDRT | N0000008656 | Decreased Hematopoiesis | PE | has_pe | tofacitinib citrate |
| MEDRT | N0000175550 | Decreased Immunologic Activity | PE | has_pe | tofacitinib |
| MEDRT | N0000175550 | Decreased Immunologic Activity | PE | has_pe | tofacitinib citrate |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| CODES | ATC | L04AF01 |
| CODES | DRUGBANK | DB08895 |
| CODES | SNOMEDCT | 704313003 |
| CODES | SNOMEDCT | 704316006 |
| CODES | VUID | 4031786 |
| SOURCES | Source | Anatomical Therapeutic Chemical |
| SOURCES | Source | Drug Bank |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Multum MediSource Lexicon |
| SOURCES | Source | National Drug Data File Plus Source Vocabulary |
| SOURCES | Source | US Edition of SNOMED_CT |
| SOURCES | Source | Veterans Health Administration National Drug File |